Dec 24- Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan. Actavis did not give any further details on the contents of the letter. In a study, the drug combination was found more effective in reducing blood pressure in patients of hypertension,...» Read More
Yeah, "Deal Or No Deal" has become a bit of a tired cliche, but I think it's totally appropriate in the context of the latest salvo in the Roche-Genentech takeover battle.
Japan and Januvia. No, it's not a country—not even a fictional one—even though it sounds like "Genovia" in "The Princess Diaries." It's a diabetes drug from Merck.
As Pfizer Chairman and CEO Jeff Kindler represents at the White House Healthcare Summit today and tries to make the industry's case against government price controls on prescription drugs, a couple of prominent industry analysts are giving him a little something to smile about.
Forget about mergers and acquisitions (M & A). Think about partnerships and acquisitions or what Leerink Swann, which specializes in healthcare stock coverage, is calling "P & A."
The morning after Genentech's big investor meeting shares of the Swiss drugmaker Roche rebounded in overseas trading and the American Despository Receipts that trade over-the-counter here in the States are following suit.
When I wasn't looking the market value of biotech giant DNA surpassed the market cap of the world's biggest drug company, Pfizer.
I'm not sure why Genentech isn't responding to Roche's media campaign. Maybe the company's and executives' lawyers are telling them to publicly keep their mouths shut outside of formal presentations like Monday's meeting. Or maybe, for whatever reason, they're decidedly taking a hardline "no media" stance and letting their press releases and SEC filings do all the talkin'.
Even though nearly every analyst this morning is saying Thursday's bloodbath was an overreaction, investors are continuing to sell biopharma stocks in the early going Friday.
Today was really ugly for biotech. The only large-cap sector stock to trade higher--and significantly--was Genentech because it's being bolstered by Roche's bond sale and increasing speculation the Swiss drugmaker is gonna have to raise its bid for DNA.
Recently, there've been scattered media reports about some drugs polluting India's slum water in alarming concentrations, according to some experts. Separately, yesterday, the U.S. Food and Drug Administration announced it's keeping India generic drugmaker Ranbaxy in the penalty box while it continues looking into whether the company fudged some data.
September 1996. I was in the middle of my nearly 10-year stint at WXYZ-TV in Detroit. And shares of Dow component Pfizer closed at $12.90. February 2009. This year will mark my ninth anniversary (man, time flies) at CNBC. And today PFE hit a new intra-day low of $12.90.
Big pharma has to change the way it sells drugs. That's the conclusion of a new PricewaterhouseCoopers report about what the industry will look like in 2020, which calls the big pharma sales model "increasingly ineffective."
This morning the world's biggest pharmaceutical firm announced that it's scrapping two more drugs that were in late-stage studies.
At the risk of offending our gracious hosts here at the Generic Pharmaceutical Association's Silver Anniversary Meeting, I wanted to talk about the seemingly incongruous venue for the event.
Is there a pipeline from the C-suite of McDonald's to the ivory towers of biopharma? At least one "Pharma's Market" reader from overseas thinks so.
The "Amgen Tour of California" is getting a lot more publicity than usual because superstar cyclists Lance Armstrong and Floyd Landis are trying to make comebacks in the race.
Yes, McDonald's has done away with "Super-Size" menu items, but I can still use the American lexicon for, hopefully, an attention-grabbing blog headline.
CardioNet caught my eye and attention when I got a research note from Rick Wise at Leerink Swann about BEAT beating the Street.
Attendance at the 4th Annual Stem Cell Summit is up, by about 50 percent, no less, over last year. All day long privately-held and publicly-traded companies are presenting to around 250 investors.
Friday the 13th. My lucky day for reaching into the Pharma's Market mailbag. Time for your Emails.